

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 27, 2001, 18:00:22 ; Search time 193.18 Seconds
(without alignments)
2323.997 Million cell updates/sec

Title: US-09-784-340-3_COPY_197_911

Perfect score: 715

Sequence: 1 atgaggctcacaagtcagc.....gtttatagtaagcgattag 715

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 730101 seqs, 313950809 residues

Total number of hits satisfying chosen parameters: 1460202

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_0601.*

```
1: /SIDS1/gcgdata/geneseq/geneseq/NA1980.DAT.*
2: /SIDS1/gcgdata/geneseq/geneseq/NA1981.DAT.*
3: /SIDS1/gcgdata/geneseq/geneseq/NA1982.DAT.*
4: /SIDS1/gcgdata/geneseq/geneseq/NA1983.DAT.*
5: /SIDS1/gcgdata/geneseq/geneseq/NA1984.DAT.*
6: /SIDS1/gcgdata/geneseq/geneseq/NA1985.DAT.*
7: /SIDS1/gcgdata/geneseq/geneseq/NA1986.DAT.*
8: /SIDS1/gcgdata/geneseq/geneseq/NA1987.DAT.*
9: /SIDS1/gcgdata/geneseq/geneseq/NA1988.DAT.*
10: /SIDS1/gcgdata/geneseq/geneseq/NA1989.DAT.*
11: /SIDS1/gcgdata/geneseq/geneseq/NA1990.DAT.*
12: /SIDS1/gcgdata/geneseq/geneseq/NA1991.DAT.*
13: /SIDS1/gcgdata/geneseq/geneseq/NA1992.DAT.*
14: /SIDS1/gcgdata/geneseq/geneseq/NA1993.DAT.*
15: /SIDS1/gcgdata/geneseq/geneseq/NA1994.DAT.*
16: /SIDS1/gcgdata/geneseq/geneseq/NA1995.DAT.*
17: /SIDS1/gcgdata/geneseq/geneseq/NA1996.DAT.*
18: /SIDS1/gcgdata/geneseq/geneseq/NA1997.DAT.*
19: /SIDS1/gcgdata/geneseq/geneseq/NA1998.DAT.*
20: /SIDS1/gcgdata/geneseq/geneseq/NA1999.DAT.*
21: /SIDS1/gcgdata/geneseq/geneseq/NA2000.DAT.*
22: /SIDS1/gcgdata/geneseq/geneseq/NA2001.DAT.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	470.6	65.8	515	20 AAV87412	EST clone BR77. H
2	190.2	26.6	1976	21 AAZ95206	Human UDP-glucuron
3	190.2	26.6	2312	21 AAZ95207	Human UGT2B15 exon
4	186.8	26.1	1323	21 AAZ95193	Human UGT2B4 exon
5	186.8	26.1	2092	21 AAZ95199	Human UDP-glucuron
6	186.2	26.0	1650	21 AAC65396	Human carbohydrate
7	179	25.0	2107	19 AAV15900	Uridine diphospho-
8	172.4	24.1	1686	21 AAZ95201	Human UGT2B7 exon
9	172.4	24.1	1854	21 AAZ95200	Human UDP-glucuron
10	124	17.3	283	21 AAA87467	Rat hepatocyte car
c 11	81	11.3	936	22 AAF58252	Oligonucleotide D1

c 12	81	11.3	936	22 AAF58254	Oligonucleotide D1
c 13	81	11.3	936	22 AAF58257	Oligonucleotide D1
c 14	81	11.3	936	22 AAF58259	Oligonucleotide D2
c 15	81	11.3	936	22 AAF58262	Oligonucleotide D2
c 16	81	11.3	938	22 AAF58255	Oligonucleotide D1
17	78.6	11.0	936	22 AAF58252	Oligonucleotide D1
18	78.6	11.0	936	22 AAF58254	Oligonucleotide D1
19	78.6	11.0	936	22 AAF58257	Oligonucleotide D1
20	78.6	11.0	936	22 AAF58259	Oligonucleotide D2
21	78.6	11.0	936	22 AAF58262	Oligonucleotide D2
22	78.6	11.0	938	22 AAF58255	Oligonucleotide D1
23	69.8	9.8	264	21 AAF15707	Human prostate can
24	64.8	9.1	1048	13 AAZ33020	UGT1E Exon 1 from
25	63.2	8.8	867	21 AAZ45113	UDP-glucuronosyltr
26	55.2	7.7	867	21 AAZ45114	UDP-glucuronosyltr
27	53.6	7.5	1105	13 AAZ45111	UGT1C Exon 1 from
28	52.2	7.3	864	21 AAZ45110	UDP-glucuronosyltr
29	52.2	7.3	2351	13 AAZ27369	HUG-Br1. Homo sap
30	52	7.3	244	22 AAF58238	Oligonucleotide D1
31	52	7.3	867	21 AAZ45112	UDP-glucuronosyltr
32	49.2	6.9	861	21 AAZ45114	UDP-glucuronosyltr
33	48.8	6.8	951	21 AAZ45115	UDP-glucuronosyltr
34	48.8	6.8	1241	13 AAZ27368	UGT1F Exon 1 from
35	48.8	6.8	2368	13 AAZ27370	HUG-Br2. Homo sap
36	45.6	6.4	1120	13 AAZ33021	UGT1D Exon 1 from
c 37	43	6.0	244	22 AAF58238	Oligonucleotide D1
38	42.4	5.9	759	21 AAZ45117	UDP-glucuronosyltr
39	41.8	5.8	8318	20 AAX20264	Borrelia burgdorfe
40	40.2	5.6	5194	20 AAX25885	C.albicans alpha-I
41	40	5.6	1483	13 AAZ33023	UGT1BP Exon 1 from
c 42	38	5.3	163319	21 AAF22306	Arabidopsis thalia
43	36.8	5.1	930	21 AAZ45116	UDP-glucuronosyltr
c 44	36.2	5.1	8011	19 AAV38336	Manic-depressive i
c 45	36.2	5.1	8065	19 AAV38335	Manic-depressive i

ALIGNMENTS

RESULT 1

AAV87412
ID AAV87412 standard; cDNA; 515 BP.

XX AC AAV87412;

XX DT 27-APR-1999 (first entry)

XX XX EST clone BR77.

XX KW Expressed sequence tag; secreted protein; haematopoiesis regulator;
XX KW tissue growth; activin; inhibin; tumour invasion suppressor; EST; human;
XX KW chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis;
XX KW receptor; ligand; anti-inflammatory; tumour inhibitor; ds.

XX OS Homo sapiens.

XX PN WO9845435-A2.

XX PD 15-OCT-1998.

XX PF 10-APR-1998; 98WO-US06954.

XX PR 10-APR-1997; 97US-0835913.

XX PA (GEMY) GENETICS INST INC.

XX PI Agostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D;

XX PI Racie LA, Spaulding V, Treacy M;

XX DR WPI; 1999-070076/06.

XX PT New polynucleotides encoding human secreted proteins - derived from
PT e.g. human blood, kidney, foetal lung, placenta, testes, brain,

PT ovary, pituitary, retina and colon cDNA libraries
 PS Claim 1; Page 556; 633pp; English.
 XX
 XX This sequence represents an expressed sequence tag (EST), and is a
 CC polynucleotide of the invention. The polynucleotides of the invention are
 CC all secreted EST sequences isolated from a variety of human tissue
 CC sources. The EST sequences and proteins encoded by them are predicted to
 CC have useful biological activities which would make them suitable for
 CC treating, preventing or ameliorating medical conditions in humans and
 CC animals, although no supporting data is given. Suggested activities,
 CC include nutritional activity, immune stimulating or suppressing activity,
 CC haematopoiesis regulating activity, tissue growth activity,
 CC activin/inhibin activity, chemotactic/chemokinetic activity,
 CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
 CC activity. The EST sequences are also stated to be useful for gene
 CC therapy.
 XX
 XX Sequence 515 BP; 148 A; 98 C; 122 G; 147 T; 0 other;

Query Match 65.8%; Score 470.6; DB 20; Length 515;
 Best Local Similarity 99.2%; Pred. No. 4.9e-126;
 Matches 473; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 1 atgaggtctgacaagtcagcttgggtattctctctcctgcagctctctctgtgtggctgt 60
 Db 33 atgaggtctgacaagtcagcttgggtattctctcctgcagctctctctgtgtggctgt 92
 Qy 61 ggattctgtggaaagtcctgtgtggtggtggtggtggtggtggtggtggtggtggtggt 120
 Db 93 ggattctgtggaaagtcctgtgtggtggtggtggtggtggtggtggtggtggtggtggt 152
 Qy 121 gtcattctagaagtcctatagtcagagccatgaggtggtggtggtggtggtggtggtggt 180
 Db 153 gtcattctagaagtcctatagtcagagccatgaggtggtggtggtggtggtggtggtggt 212
 Qy 181 cctctgtaattgactacaggaagcctctctgctgctgctgctgctgctgctgctgctgctg 240
 Db 213 cctctgtaattgactacaggaagcctctctgctgctgctgctgctgctgctgctgctgctg 272
 Qy 241 caggacacagagaagaaataaattttgtgacctgacctgacctgacctgacctgacctg 300
 Db 273 caggacacagagaagaaataaattttgtgacctgacctgacctgacctgacctgacctg 332
 Qy 301 ttatcaacctggcaatcagttataaaattaaatgattttttttgtgaaataagaggaact 360
 Db 333 ttatcaacctggcaatcagttataaaattaaatgattttttttgtgaaataagaggaact 392
 Qy 361 ttaaaatgatgtgagagcttattctacacacagacattataagaagctacagaa 420
 Db 393 ttaaaatgatgtgagagcttattctacacacagacattataagaagctacagaa 452
 Qy 421 accaactacagataacgctttatagacctgtgattccctcggtggagacctgatgct 477
 Db 453 accaactacagataacgctttatagacctgtgattccctcggtggagacctgatgct 509

RESULT 2
 AAZ95206
 ID AAZ95206 standard; DNA; 1976 BP.
 XX
 AC AAZ95206;
 XX
 XX 05-JUN-2000 (first entry)
 XX Human UDP-glucuronosyltransferase 2B15 nucleotide sequence.
 XX
 KW UDP-glucuronosyltransferase 2B15; UGT2B15; polymorphism; metabolism;
 KW drug interaction; detect; human; single nucleotide polymorphism;
 KW SNPs; ds.
 XX

OS Homo sapiens.
 XX WO200006776-A1.
 PN
 XX
 PD 10-FEB-2000.
 XX
 XX 22-JUL-1999; 99WO-US16675.
 PF
 XX 28-JUL-1998; 98US-0094391.
 PR
 XX (AXYS-) AXYS PHARM INC.
 PA
 XX Galvin M, Miller A, Penny L, Riedy M;
 PI WPI; 2000-195321/17.
 XX P-PSDB; AAY78935.
 DR
 XX Novel human UDP-glucuronosyltransferase sequence, polymorphisms for
 PT genotyping individuals to predict rate of metabolism of substrates and
 PT for identifying potential drug interactions
 XX
 XX Disclosure; Page 56-59; 72pp; English.
 PS
 XX This sequence represents the human UDP-glucuronosyltransferase 2B15
 CC (UGT2B15) gene. UDP-glucuronosyltransferase (UGTs) are a family of
 CC enzymes that catalyse the glucuronic acid conjugation of a wide range of
 CC endogenous and exogenous substrates. The UGT2B gene subfamily encode
 CC steroid metabolizing isoforms in the liver. Alteration of the expression
 CC or function of UGTs may effect drug metabolism. The invention relates to
 CC non-chromosomal nucleic acid molecules, which comprise human UGT2B
 CC sequence polymorphisms (see AAZ95051-95110). Probes which detect the
 CC UGT2B locus polymorphisms can be used to detect altered UGT2B metabolism
 CC of a substrate in an individual. The nucleic acid molecules comprising a
 CC human UGT2B sequence polymorphism can be used in screening assays for
 CC genotyping individuals, also to predict their rate of metabolism of
 CC UGT2B substrate, potential drug-drug interactions and adverse side
 CC effects. The polymorphisms can be used as single nucleotide polymorphisms
 CC (SNPs) for detecting genetic linkage related to phenotypic variation in
 CC activity or expression of UGT2B protein. The polymorphism containing
 CC nucleic acid molecules may also be used for generating genetically
 CC modified non-human animals and for obtaining site specific gene
 CC modification in cell lines.
 XX
 XX Sequence 1976 BP; 594 A; 368 C; 419 G; 595 T; 0 other;

Query Match 26.6%; Score 190.2; DB 21; Length 1976;
 Best Local Similarity 56.0%; Pred. No. 5.5e-45;
 Matches 407; Conservative 0; Mismatches 308; Indels 12; Gaps 2;
 Qy 1 atgaggtctgacaagtcagcttgggtattctctcctgcagctctctctgt---gttggc 57
 Db 8 aggatgtctctgaaatggacgcagctctctctctgtgacagctcagcttcttacttgcg 67
 Qy 58 tgtgagattctggaaagtcctgtgtgcccctgtgacatgagccattggcttaattgc 117
 Db 68 tctggaagctgtgaaaggtgtctagctgtgcccacagaataacagccattggataaattg 127
 Qy 118 aaggtcattctagaagctcatagtgagagggccatgaggtgaggtgaggtgaggtgaggtg 177
 Db 128 aagacaatccctggaagagctgtgttcagaggggtcagctgaggtgaggtgaggtgaggt 187
 Qy 178 aagcctctgtaattgactacaggaagcctctctcctgataaattgaggtggtggtccatg 237
 Db 188 gcttctctctgtcaatgcccagtaaatcctctgctgtatagattagagatttatcttaca 247
 Qy 238 cc-----acaggacagacaagaagaataaataatggttgacctgagctggaat 288
 Db 248 tctttaactaaataatgatttggaagattctctctgtgaaatctctgagatagatgatat 307
 Qy 289 gtcttgccaggttctatcaacctggcaatcagttataaataatgattttgtttgtaa 348
 Db 308 ggtgtttcaaaaaatacattttgtgtcattttttcacaaataacagaagactgtgtgtggaa 367

QY 349 ataagaggaacttaaaatgatgtgtgagagctttatctacaaatcagacacattatgaag 408
DB 368 tattatgactacagtaacaagcctctgaaagatgcaggtttgtaataagaacattatgatg 427
QY 409 aagctacagagaacccaactacagcttaacgctttatagaccctgtgattccctggagac 468
DB 428 aaactacaagagtcacaaagtgtgactcattctgcagatgcccttaaccctgtgtgag 487
QY 469 ctatggctgagtgcttccagctccctttgtgtcacaacttagaacttctcctaagaggc 528
DB 488 ctactggctgaactatttaacatacccttctgtacagcttctcgtattctgtgtgctac 547
QY 529 aatatggagcgaagctgtggaaacttccagctccactttctctatgtaccctgtgctatg 588
DB 548 acatttgagaagaatggtgaggtattctgttccctctctctatgtaccctgtgttatg 607
QY 589 acaggactaacagacagaaatgaccttcttgaaagatgaaataaattcaattccttcagtt 648
DB 608 tcagaattaagtatcaaatgatttctatgagaggagataaaaaaatatgatacatatgctt 667
QY 649 ttgtccacttctggatcaggattacgactatcatttttgggaagagtttttatagtaag 708
DB 668 tatttgactttgtttcaatttcatctgaaagattgagggagaccagtttttatagtaa 727
QY 709 gcattag 715
DB 728 gttctag 734

RESULT 3

ID AAZ95207 standard; DNA; 2312 BP.
XX AAZ95207;
AC AAZ95207;
DT 05-JUN-2000 (first entry)
DE Human UGT2B15 exon 1 nucleotide sequence.
XX
KW UDP-glucuronosyltransferase 2B15; UGT2B15; polymorphism; metabolism;
KW drug interaction; detect; human; single nucleotide polymorphism;
KW SNPs; ds.
XX
OS Homo sapiens.
XX
PN WO200006776-A1.
XX
PD 10-FEB-2000.
XX
PF 22-JUL-1999; 99WO-US16675.
XX
PR 28-JUL-1998; 98US-0094391.
XX
PA (AXYS-) AXYS PHARM INC.
XX
PI Galvin M, Miller A, Penny L, Riedy M;
XX WPI; 2000-195321/17.
XX
PT Novel human UDP-glucuronosyltransferase sequence, polymorphisms for
PT genotyping individuals to predict rate of metabolism of substrates and
PT for identifying potential drug interactions
XX
PS Example 3; Page 60-61; 72pp; English.
XX
CC This sequence represents the nucleotide sequence of exon 1 of the human
CC UDP-glucuronosyltransferase 2B15 (UGT2B15) gene.
CC
CC UDP-glucuronosyltransferase (UGTs) are a family of enzymes that catalyze
CC the glucuronic acid conjugation of a wide range of endogenous and
CC exogenous substrates. The UGT2B gene subfamily encode steroid
CC metabolizing isoforms in the liver. Alteration of the expression or
CC function of UGTs may effect drug metabolism. The invention relates to

CC non-chromosomal nucleic acid molecules, which comprise human UGT2B
CC sequence polymorphisms. Probes which detect the UGT2B locus polymorphisms
CC can be used to detect altered UGT2B metabolism of a substrate in an
CC individual. The nucleic acid molecules comprising a human UGT2B sequence
CC polymorphism can be used in screening assays for genotyping individuals,
CC also to predict their rate of metabolism of UGT2B substrate, potential
CC drug-drug interactions and adverse side effects. The polymorphisms can be
CC used as single nucleotide polymorphisms (SNPs) for detecting genetic
CC linkage related to phenotypic variation in activity or expression of
CC UGT2B protein. The polymorphism containing nucleic acid molecules may
CC also be used for generating genetically modified non-human animals and
CC for obtaining site specific gene modification in cell lines.

XX
SQ Sequence 2312 BP; 765 A; 360 C; 414 G; 773 T; 0 other;

Query Match 26.6%; Score 190.2; DB 21; Length 2312;
Best Local Similarity 56.0%; Pred. No. 5.9e-45;
Matches 407; Conservative 0; Mismatches 308; Indels 12; Gaps 2;

QY 1 atgagctgtgacaagtcagcttgggtatttctgtcctcctgcagctctctgt---gttggc 57
DB 699 aggatgtctctgaaatggacgtcagctcttctgtcgtacagctcagttgtactttagc 758
QY 58 tgtgattctgtgggaagctcctggtgtggtggtggtggtggtggtggtggtggtggtg 117
DB 759 tctggagctgtgggaaggtggtggtggtggtggtggtggtggtggtggtggtggtggt 818
QY 118 aagctcattctagaagagctcagtgagggccatgagagtgagtgagtgagtgagtgagtg 177
DB 819 aagacaatcctggagagctgtgtcagaggggtcagtgagtgagtgagtgagtgagtgag 878
QY 178 aagcctctgttaattgactacaggaagccttctgtcctcctgaggtggtggtggtggtg 237
DB 879 gcttctactctgtcaatgccagtaaatcatctgtctattaaattagagttatcctaca 938
QY 238 cc-----acaggacagacagacagaaatgaaatat:tggtacctagctcgaat 288
DB 939 tcttaactaaaaatgatttgggaagcttctctgaaaattctcgtatagatgagtgatat 998
QY 289 gtctgccaggcttatacactggaatcagttataataataatgattttttgttgaa 348
DB 999 ggtgttcaaaaaatacatttgggtcatatttttccaaatcacaagaattgtgtggaa 1058
QY 349 ataagaggaactttaaaaatgatgtgtgagagctttatctacaaatcagacacattatgaag 408
DB 1059 tattatgactacagtaacaagctctgaaagatgcagtttgaataagaacattatgatg 1118
QY 409 aagctacagagaacccaactacagcttaacgcttataagcctgtgattccctcgtgagac 468
DB 1119 aaactacaagagtcacaaagtgtgactcattctgtgagagtccttaaccctgtgtgag 1178
QY 469 ctgagctgaggtgtctccagctcccttctgtgctcacacttagaacttctcctaagaggc 528
DB 1179 ctactggtgaaactatttaacatacccttctgtacagcttctcgttctcgttctgctac 1238
QY 529 aatatggagcgaagctgtggaaacttccagctcccttctgtacacacttagaacttctcctaagaggc 588
DB 1239 acatttgagaagaatggtgaggtattctgttccctcctctctatgtacactgtgttatg 1298
QY 589 acaggactaacagacagaaatgaccttctgaaagagtgataaaataatcattccttcagtt 648
DB 1299 tcagaattaagtatcaaatgatttctcagtgagagagata:aaatgatgatacatgctt 1358
QY 649 ttgttccacttctgaggtcaggtattacgactatcattt:agaaagattttatagtaag 708
DB 1359 tatttgactttgtttcaaatttatgatctgaagaat:ggaccagttttatagtgaa 1418
QY 709 gcattag 715
DB 1419 gttctag 1425

[illegible]

PT genotyping individuals to predict rate of metabolism of substrates and
 PT for identifying potential drug interactions

XX Disclosure; Page 34-36; 72pp; English.

XX This sequence represents the human UDP-glucuronosyltransferase 2B4
 CC (UGT2B4) gene. UDP-glucuronosyltransferase (UGTs) are a family of
 CC enzymes that catalyse the glucuronic acid conjugation of a wide range of
 CC endogenous and exogenous substrates. The UGT2B gene subfamily encode
 CC steroid metabolizing isoforms in the liver. Alteration of the expression
 CC or function of UGTs may effect drug metabolism. The invention relates to
 CC non-chromosomal nucleic acid molecules, which comprise human UGT2B
 CC sequence polymorphisms (see AA295051-295110). Probes which detect the
 CC UGT2B locus polymorphisms can be used to detect altered UGT2B metabolism
 CC of a substrate in an individual. The nucleic acid molecules comprising a
 CC human UGT2B sequence polymorphism can be used in screening assays for
 CC genotyping individuals, also to predict their rate of metabolism of
 CC UGT2B substrate, potential drug-drug interactions and adverse side
 CC effects. The polymorphisms can be used as single nucleotide polymorphisms
 CC (SNPs) for detecting genetic linkage related to phenotypic variation in
 CC activity or expression of UGT2B protein. The polymorphism containing
 CC nucleic acid molecules may also be used for generating genetically
 CC modified non-human animals and for obtaining site-specific gene
 CC modification in cell lines.

XX Sequence 2092 BP; 639 A; 398 C; 438 G; 617 T; 0 other;

Query Match 26.1%; Score 186.8; DB 21; Length 2092;
 Best Local Similarity 55.7%; Pred. No. 5.4e-44;
 Matches 403; Conservative 0; Mismatches 312; Indels 9; Gaps 2;

QY 1 atgaggtctgacagtcagcttgggtattctctgtcgtcagctctctctgt---gttggc 57
 DB 35 aggatgtctatgaatgacttcagctctctctgtcgtacacgtgagctgtactcttgc 94
 QY 58 tggagattcttgaggaaagctgggtggtgcccctgtgacatgacattgcttaagtgc 117
 DB 95 tcggggagttgtggaagggtgctgggtggccacagatccagcactggatgaatata 154
 QY 118 aaggtcattctagaagagctcactagtagagagccatgagtagcagattgactcactca 177
 DB 155 aagacatctcgatgaactgtccagagaggtcatgaggtgactgtattggcatcttca 214
 QY 178 aagccttcgttaattgactacaggaagcctctcgtcattgaaatttgaggtgctccatg 237
 DB 215 gcttccattcttcgactccacagcccatctactcttaattgaagttatctcgtga 274
 QY 238 ccacaggacagacagaaagaatgaaatattgttgacctagctctga-----atgctc 291
 DB 275 tccttaactaaaactgagttgaggatattatcaagcagctggttaagagatgggcagaa 334
 QY 292 ttgcccaggttatcaacctggcgaatcagttataaaattaaatgatttttgttgaaata 351
 DB 335 ctcccaaaagacacattttgtgcataatttttcaacagtaacaaatcatgtggacattt 394
 QY 352 agaggaaacttaaaatgatgtgtgagagctttatctacaaatcagacacttatgaagaag 411
 DB 395 aatgacatacttaagaagttctgtgaaggatagattttcaaatgaagaacttatgaagaaa 454
 QY 412 ctacaggaacacacactacagatgataacgcttatagacctgtgattccccctggagacctg 471
 DB 455 ctacagagtcagagatttgatgtgtgttctgcagatgctgtttccctctgtgtgagctg 514
 QY 472 atggctgagttgtctcagtcctttttgtgctcacacttagaactctcctaaagggcgaat 531
 DB 515 ctggccgaggttaactaaataacacctttgtctacagctccgcctctctctcctggtacgca 574
 QY 532 atggagcagagcttgaggaaactccacgtccactcttcttatgacctgtgacctgacaa 591
 DB 575 attgaaaagcatagtgaggagactctgttccctctctctctctctctgtgtgttatgca 634
 QY 592 ggactaacagacagaatgacctttctggaaagagtgaaaaaattcaatgcttccagtttg 651

DB 635 gaactaagtaccacaaatgacttctcatagagagggtaaaaa..tatgatctatgtctttat 694
 QY 652 ttccactcttgattcaggattacgactatcatttttggggagagttttatagtaagca 711
 DB 695 ttgaattttgttccaaatattgacatgaagaagtggtttcagttctacagtgaaagtt 754
 QY 712 ttag 715
 DB 755 ctag 758

RESULT 6

AAC65396

ID AAC65396 standard; cDNA; 1650 BP.

XX AAC65396;

XX 13-FEB-2001 (first entry)

DE Human carbohydrate-modifying enzyme cDNA Incyte ID No: 2912330CB1.

XX Human: carbohydrate-modifying enzyme; CME; antidiabetic;

KW immunosuppressive; anti-HIV; antiinflammatory; antianaemic;

KW antiasthmatic; antiarteriosclerotic; antithyroid; hepatotropic;

KW nephrotropic; antitumor; thymimetic; neuroprotective; osteopathic;

KW antiarthritic; antipsoriatic; uropathic; ophthalmological;

KW dermatological; antilulcer; cytostatic; virucide; antibacterial;

KW fungicide; protozoacide; tranquiliser; vulnerary; diabetes;

KW autoimmune disorder; inflammatory disorder; infection; ss.

XX Homo sapiens.

XX WO200063351-A2.

XX 26-OCT-2000.

XX 20-APR-2000; 2000WO-US10882.

XX 21-APR-1999; 99US-0130383.

XX (INCY-) INCYTE GENOMICS INC.

XX Lal P, Yue H, Tang YT, Hillman JL, Baughn NR, Yang J;

XX WPI; 2000-672729/65.

XX P-PSDB; AAB28677.

PT Novel carbohydrate modifying enzyme polypeptides and polynucleotides
 PT for diagnosis, treatment, and prevention of carbohydrate metabolism
 PT disorders, autoimmune/inflammatory disorders, and cancer

XX Claim 4; Page 75; 75pp; English.

XX The present cDNA sequence encodes a human carbohydrate-modifying enzyme
 CC (CME). CME polynucleotides and polypeptides are useful for treating and
 CC diagnosing diseases associated with CME such as diabetes,
 CC autoimmune/inflammatory disorders such as AIDS, Addison's disease,
 CC adult respiratory distress syndrome, allergies, anaemia, asthma,
 CC atherosclerosis, autoimmune thyroiditis, bronchitis, cholecystitis,
 CC contact dermatitis, Crohn's disease, emphysema, erythroblastosis fetalis,
 CC glomerulonephritis, Good pasture's syndrome, gout, Grave's disease,
 CC Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis,
 CC osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis,
 CC Reiter's syndrome, arthritis, scleroderma, Sjogren's syndrome, systemic
 CC lupus erythematosus, ulcerative colitis, uveitis, Werner syndrome, systemic
 CC complications of cancer, haemodialysis, and extracorporeal circulation,
 CC viral, bacterial, fungal parasitic, protozoal, and helminthic infections,
 CC trauma, or cancer. CME, or its catalytic or immunogenic fragment, is
 CC useful for drug screening.

XX Sequence 1650 BP; 489 A; 330 C; 354 G; 477 T; 0 other;

Query Match	26.0%	Score 186.2	DB 21	Length 1650
Best Local Similarity	55.4%	Pred. No. 7.2e-44		
Matches 384	Conservative 0	Mismatches 303	Indels 6	Gaps 1
29	ttctgctcctgcagctctctgtgttgctgtggattctgtgggaagctcctgtgtgccc	88		
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				
61				
62				
63				
64				
65				
66				
67				
68				
69				
70				
71				
72				
73				
74				
75				
76				
77				
78				
79				
80				
81				
82				
83				
84				
85				
86				
87				
88				
89				
90				
91				
92				
93				
94				
95				
96				
97				
98				
99				
100				
101				
102				
103				
104				
105				
106				
107				
108				
109				
110				
111				
112				
113				
114				
115				
116				
117				
118				
119				
120				
121				
122				
123				
124				
125				
126				
127				
128				
129				
130				
131				
132				
133				
134				
135				
136				
137				
138				
139				
140				
141				
142				
143				
144				
145				
146				
147				
148				

05-JUN-2000 (first entry)
Human UDP-glucuronosyltransferase 2B7 nucleotide sequence.
UPP-glucuronosyltransferase 2B7; UGT2B7; polymorphism; metabolism; SNPs;
drug interaction; detect; human; single nucleotide polymorphism; ds.
Homo sapiens.
WO200006776-A1.
10-FEB-2000. 99WO-US16675.
22-JUL-1999; 98US-0094391.
28-JUL-1998; 98US-0094391.
(AXYS-) AXYS PHARM INC.
Galvin M, Miller A, Penny L, Riedy M;
WPI; 2000-195321/17.
P-PSDB; AAY78934.
Novel human UDP-glucuronosyltransferase sequence, polymorphisms for
genotyping individuals to predict rate of metabolism of substrates and
for identifying potential drug interactions
Disclosure; Page 41-44; 72pp; English.
This sequence represents the human UDP-glucuronosyltransferase 2B7
(UGT2B7) gene. UDP-glucuronosyltransferase (UGTs) are a family of
enzymes that catalyze the glucuronic acid conjugation of a wide range of
endogenous and exogenous substrates. The UGT2B gene subfamily encode
steroid metabolizing isoforms in the liver. Alteration of the expression
or function of UGTs may effect drug metabolism. The invention relates to
non-chromosomal nucleic acid molecules, which comprise human UGT2B
sequence polymorphisms (see A293051-295110). Probes which detect the
UGT2B locus polymorphisms can be used to detect altered UGT2B metabolism
of a substrate in an individual. The nucleic acid molecules comprising a
human UGT2B sequence polymorphism can be used in screening assays for
genotyping individuals, also to predict their rate of metabolism of
UGT2B substrate, potential drug-drug interactions and adverse side
effects. The polymorphisms can be used as single nucleotide polymorphisms
(SNPs) for detecting genetic linkage related to phenotypic variation in
activity or expression of UGT2B protein. The polymorphism containing
nucleic acid molecules may also be used for generating genetically
modified non-human animals and for obtaining site specific gene
modification in cell lines.
Sequence 1854 BP; 572 A; 338 C; 392 G; 552 T; 0 other;
Query Match 24.1%; Score 172.4; DB 21; Length 1854;
Best Local Similarity 54.4%; Pred. No. 7.2e-40;
Matches 394; Conservative 0; Mismatches 321; Indels 9; Gaps 2;
QY 1 atgaggtctgacagtcagcttggtgatttctgctcagct---ctctgtgtgctg 57
DB 12 agdgtctgtgaatggagctcagtaatttctgctatacaacagctgcttctttagc 71
QY 58 tgtggtatctgtggaaagtcctggtggtgcccctgtgacatgagccattggttaatgctc 117
DB 72 tctgggaattgtgaaaggctggtggtggcagcagaatacagccattggatgaatata 131
QY 118 aaggtcattctagaagagctcagtagtgagagccatgaggttaacagattgactactca 177
DB 132 aagacaatctctgagctgatttctgagaggtcaggtgagctgactgctgcttcttca 191
QY 178 aagccttcgttaattgactacagagccttctgctgactgaaattgaggtggtccatag 237
DB 192 gcttccattcttttgatcccaacaactcctcgtcttaaaattgaaattatcccaaca 251

QY 238 ccacaggacagacagagaaatgaaatatttggacttggacttgcctga-----atgtc 291
DB 252 tctttaactaaacagagtggtggagaatttcatcatgcaacattaaagagatggcagac 311
QY 292 ttgccaggcttatcaaacctggcaatcagttataaataaattgatttttttttgaata 351
DB 312 ctccaaaagatacatttgggttataatttttcacaagtagcagaatcatgtcaatattt 371
QY 352 agaggaaactttaaaatgatgtgtgagagcttattctacaacacacacttatgaagaag 411
DB 372 ggtgacataactagaagttctgtgaaagatgtagttccanataagaataatttatgaaaaa 431
QY 412 ctacagaaac 471
DB 432 gtacaagagtcgaagatttgacgtcatttttgcagagctatttttccctgtagtgagctg 491
QY 472 atggctgagttgcttccagtccttttggctgcacacttagaacttctctaaagagcaat 531
DB 492 ctggctgagctatttaacatacctttgtgacagctcctcctcctcctcctcctcctcact 551
QY 532 atggagcgaagctgtggaaacttccagctccacttcccttctgctacctgtgcctatgaca 591
DB 552 ttgaaaaagcatagtgaggagatttatttccctcctcctcctcctcctcctcctcctc 611
QY 592 ggactaacacagacagatgacaccttctctggaaagagtagtaaaattccaatgtcttcagtttg 651
DB 612 gaattactgatcaaatgacttttcatgagagggtaaaataatgatctatgtgctttac 671
QY 652 ttcaacttctgagtcagagattacagactcatttttgggagagagttttatagtaggca 711
DB 672 ttgacttttggctcgaaatatttgacatgaagaagcggggtcagttttatagtaggaatt 731
QY 712 tttag 715
DB 732 cttag 735
RESULT 10
AAA87467
ID AAA87467 standard; DNA; 283 BP.
XX
AC AAA87467;
DT 08-JAN-2001 (first entry)
XX
DE Rat hepatocyte carcinogenesis biomarker nucleic acid SEQ ID NO:391.
XX
KW Rat; phenobarbital; carcinogenesis marker; carcinogenesis; detection;
XX identification; carcinogenic; probe; primer.
XX
OS Rattus norvegicus.
XX
PN WO200044902-A2.
XX
PD 03-AUG-2000.
XX
PF 28-JAN-2000; 2000WO-US00503.
XX
PR 29-JAN-1999; 99US-0118078.
XX
PA (SEAR) SEARLE & CO G D.
XX
PI Bunch RT, Curtis SW, Rodi CP, Morris DL;
XX
XX WPI; 2000-505977/45.
XX
PT New nucleic acid encoding a carcinogenic biomarker, induced by
PT phenobarbital treatment of rat hepatocytes, useful for identifying
PT carcinogenic compounds
XX
PS Claim 1; Page 184; 240pp; English.
XX
CC AAA87080 to AAA87656 represent nucleic acid sequences (N1) encoding a

01-FEB-2001.
26-JUL-2000; 2000WO-US20476.
26-JUL-1999; 99US-0145695.
17-MAR-2000; 2000US-0190259.
(CLIN-) CLINICAL MICRO SENSORS INC.
Umek RM;
WPI; 2001-159728/16.
Nucleic acids containing electron-transfer group, useful as labels in hybridization assays, e.g. for genotyping, allowing repeat analyses on a single surface
Example 6; Page 127; 159pp; English.
The present invention relates to a composition comprising two nucleic acids each containing an electron-transfer group (ETM) having different redox potentials. The invention is used for electronic detection of nucleic acids, especially of substitutions (mismatches) and single-nucleotide polymorphisms, e.g. for genotyping, monitoring gene expression.
Sequence 936 BP; 4 A; 144 C; 7 G; 5 T; 776 other;
Query Match 11.3%; Score 81; DB 22; Length 936;
Best Local Similarity 1.0%; Pred. No. 1.2e-13;
Matches 6; Conservative 362; Mismatches 237; Indels 0; Gaps 0;
QY 110 ttaatgtcaagtcattcttagaagcctcatgtgagaggccatgaggttaacagattga 169
DB 664 WWWWWW... 605
QY 170 ctcaactcaagccttgtaattgactacagagcctctgcattgaaattgaggtgg 229
DB 604 WWWWWW... 545
QY 230 tccatgtccacagagccttcgttaattgactacagagcctctgcattgaaattgaggtgg 229
DB 604 WWWWWW... 545
QY 230 tccatgtccacagagccttcgttaattgactacagagcctctgcattgaaattgaggtgg 229
DB 544 WWWWWW... 485
QY 290 tctgtccaggcttcaaaccttgccatcaggttataaaattaaatgattttttgttgaaa 349
DB 484 WWWWWW... 425
QY 350 taaggaggaactttaaaatgatgtgagagcctttatctacacacacattatgaaga 409
DB 424 WWWWWW... 365
QY 410 agctacagaaacacactacagatgtacacgttatagacccctgtgattccctggagacc 469
DB 364 WWWWWW... 305
QY 470 tgatgctgagtgcttcagtcctcttctgtgctacacttagaactctcctaaaggcca 529
DB 304 WWWWWW... 245
QY 530 atatgagcgaagctgtgggaaactccagctccacttctcctatgtacctgtgcctatga 589
DB 244 WWWWWW... 185
QY 590 caggactaacagacagaatgaccttcttggaagagataaaattcaalgcttctcagttt 649
DB 184 WWWWWW... 125
QY 650 tgttccactctgattcaggattacgactatcatcttttgggagaggttttatagtaagg 709
DB 124 WWWWWW... 65

QY 710 catta 714
DB 64 WWWWW 60
RESULT 13
AAF58257/C
ID AAF58257 standard; DNA; 936 BP.
XX
AC AAF58257;
XX
DT 24-APR-2001 (first entry)
XX
DE Oligonucleotide D1954.
XX
KW Electron-transfer group; ETM; mismatch; genotyping;
KW gene expression; ss.
XX
OS Synthetic.
XX
PN WO200107665-A2.
XX
PD 01-FEB-2001.
XX
PF 26-JUL-2000; 2000WO-US20476.
XX
PR 26-JUL-1999; 99US-0145695.
PR 17-MAR-2000; 2000US-0190259.
XX
PA (CLIN-) CLINICAL MICRO SENSORS INC.
XX
PI Umek RM;
XX
XX WPI; 2001-159728/16.
XX
PT Nucleic acids containing electron-transfer group, useful as labels in hybridization assays, e.g. for genotyping, allowing repeat analyses on a single surface
XX
PT Example 6; Page 127; 159pp; English.
XX
PS The present invention relates to a composition comprising two nucleic acids each containing an electron-transfer group (ETM) having different redox potentials. The invention is used for electronic detection of nucleic acids, especially of substitutions (mismatches) and single-nucleotide polymorphisms, e.g. for genotyping, monitoring gene expression.
XX
SQ Sequence 936 BP; 5 A; 142 C; 7 G; 6 T; 776 other;
Query Match 11.3%; Score 81; DB 22; Length 936;
Best Local Similarity 1.0%; Pred. No. 1.2e-13;
Matches 6; Conservative 362; Mismatches 237; Indels 0; Gaps 0;
QY 110 ttaatgtcaagtcattcttagaagcctcatgtgagaggccatgaggttaacagattga 169
DB 664 WWWWWW... 605
QY 170 ctcaactcaagccttcgttaattgactacagagcctctgcattgaaattgaggtgg 229
DB 604 WWWWWW... 545
QY 230 tccatgtccacagagccttcgttaattgactacagagcctctgcattgaaattgaggtgg 229
DB 544 WWWWWW... 485
QY 290 tctgtccaggcttcaaaccttgccatcaggttataaaattaaatgattttttgttgaaa 349
DB 484 WWWWWW... 425
QY 350 taaggaggaactttaaaatgatgtgagagcctttatctacacacacattatgaaga 409
DB 424 WWWWWW... 365
QY 410 agctacagaaacacactacagatgtacacgttatagacccctgtgattccctggagacc 469
DB 364 WWWWWW... 305
QY 470 tgatgctgagtgcttcagtcctcttctgtgctacacttagaactctcctaaaggcca 529
DB 304 WWWWWW... 245
QY 530 atatgagcgaagctgtgggaaactccagctccacttctcctatgtacctgtgcctatga 589
DB 244 WWWWWW... 185
QY 590 caggactaacagacagaatgaccttcttggaagagataaaattcaalgcttctcagttt 649
DB 184 WWWWWW... 125
QY 650 tgttccactctgattcaggattacgactatcatcttttgggagaggttttatagtaagg 709
DB 124 WWWWWW... 65

[illegible]

RESULT 14
AAF58259/C
ID AAF58259 standard; DNA: 936 BP.

XX	WP1; 2001-159728/16.
DR	
XX	
PT	Nucleic acids containing electron-transfer group, useful as labels in hybridization assays, e.g. for genotyping, allowing repeat analyses on a single surface -
PT	

The present invention relates to a composition comprising two nucleic acids each containing an electron-transfer group (ETM) having different redox potentials. The invention is used for electronic detection of nucleic acids, especially of substitutions (mismatches) and single-nucleotide polymorphisms, e.g. for genotyping, monitoring gene expression.

Sequence 936 BP; 6 A; 138 C; 8 G; 8 T; 776 other: 22 A

[illegible]

RESULT 15
AAF58262/c
ID AAF58262 standard: DNA: 936 BP.

Job time: 8372 sec

[illegible]

Search completed: August 27, 2001, 18:00:29

THIS PAGE BLANK (USPTO)